The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

NCT00108823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG: Roflumilast

Sponsor

AstraZeneca